Literatur
-
1
Agarwal S, Zaman T, Handa R.
Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Singapore Med J.
2009;
50
686-692
-
2
Aletaha D, Stamm T, Kapral T. et al .
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
Ann Rheum Dis.
2003;
62
944-951
-
3
Antony T, Jose VM, Paul BJ. et al .
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis.
Indian J Med Sci.
2006;
60
318-326
-
4
Curtis JR, Beukelman T, Onofrei A. et al .
Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide.
Ann Rheum Dis.
2010; 69;
43–47
-
5 Glaeske G, Schicktanz C, Janhsen K. GEK-Arzneimittel-Report 2009. Schriftenreihe zur Gesundheitsanalyse, Band 68. St. Augustin: Asgard; 2009
-
6
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF. et al .
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum.
2005;
52
3381-3390
-
7
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF. et al .
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
Ann Intern Med.
2007;
146
406-415
-
8
Grigor C, Capell H, Stirling A. et al .
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet.
2004;
364
263-269
-
9
Gromnica-Ihle E.
Pharmakotherapie der rheumatoiden.
Arthritis. Z Rheumatol.
2002;
61
((Suppl 2))
II/35-II/38
-
10
Korpela M, Laasonen L, Hannonen P. et al .
for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study group.
Arthritis Rheum.
2004;
50
2072-2081
-
11
Kremer J, Genovese M, Cannon GW. et al .
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomi-zed, double-blind, placebo controlled trial.
J Rheumatol.
2004;
31
1521-1531
-
12
Kremer JM, Genovese MC, Cannon GW. et al .
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial.
J Rheumatol.
2004;
31
1521-1531
-
13
Lee SS, Park YW, Park JJ. et al .
Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
Scand J Rheumatol.
2009;
38
11-14
-
14
Leirisalo-Repo M, Kautiainen H, Laasonen L, Möttönen T. et al .
A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACO DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACO study.
Ann Rheum Dis.
2008;
67
((Suppl II))
50
-
15
Möttönen T, Hannonen P, Leirisalo-Repo M. et al .
for the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial.
Lancet.
1999;
353
1568-1573
-
16
O’Dell JR, Haire CE, Erikson N. et al .
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
N Engl J Med.
1996;
334
1287-1291
-
17
O’Dell JR, Leff R, Paulsen G. et al .
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum.
2002;
46
1164-1170
-
18
Proudman SM, Keen HI, Stamp LK. et al .
Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Semin Arthritis Rheum.
2007;
37
99-111
-
19
Puolakka K, Kautiainen H, Mottonen T. et al .
for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five year experience from the FIN-RACo trial.
Arthritis Rheum.
2005;
52
36-41
-
20
Rantalaiho V, Korpela M, Hannonen P. et al .
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Arthritis Rheum.
2009;
60
1222-1231
-
21
Saunders SA, Capell HA, Stirling A. et al .
Triple therapy in early active rheumatoid arthritis. A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Arthritis Rheum.
2008;
58
1310-1317
-
22
Schoels M, Kapral T, Stamm T. et al .
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Ann Rheum Dis.
2007;
66
1059-1065
-
23
Sokka T, Pincus T.
Rheumatoid arthritis: strategy more important than agent.
Lancet.
2009;
374
459-466
-
24
Van den Hout WB, Goekoop-Ruiterman YP, Allaart CF. et al .
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
Arthritis Rheum.
2009;
61
291-299
-
25
van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP. et al .
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Ann Rheum Dis.
2007;
66
1356-1362
-
26
Vollenhoven van R F, Ernestam S, Geborek P. et al .
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
Lancet.
2009;
374
459-466
-
27
Weinblatt ME, Kremer JM, Coblyn JS. et al .
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Arthritis Rheum.
1999;
42
1322-1328
-
28
Wollenhaupt J, Alten R, Backhaus M. et al .
Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009.
Akt Rheumatol.
2009;
34
234-239
-
29
Wollenhaupt J, Alten R, Burkhardt H. et al .
Aktuelle Therapiestrategien bei rheumatoider Arthritis. Entzündung rasch beherrschen ist entscheidend für die Prognose.
MMW.
2006;
148
((Heft 42))
38-42
-
30
Zeidler H, Wollenhaupt J.
Kombination von Basistherapeutika. Von der individuellen Hoffnung zum gezielten Einsatz.
Z Rheumatol.
2001;
60
477-480
Korrespondenzadresse
Prof. Dr. med. Henning Zeidler
Facharzt für Innere Medizin
Rheumatologie und Physikalische Medizin
Rheumatologikum Hannover
Rathenaustraße 13/14
30159 Hannover
Phone: +49/0511/301 54 20
Fax: +49/0511/ 301 54 45
Email: zeidler@rheumatologikum.de
